Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9824509 | 0.92 | HDAC3 (0.59) | BCHEACHEHDAC3HDAC1HDAC2 | |
| Ethylene SCHEMBL9824504 | 0.89 | HDAC3 (0.56) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL24685749 | 0.86 | HDAC3 (0.50) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL16727723 | 0.85 | HDAC1 (0.63) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL6264194 | 0.84 | NPC1 (0.50) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL19261311 | 0.83 | RORC (0.55) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL18379359 | 0.83 | LMNA (0.52) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL18379381 | 0.83 | BCHE (0.44) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL8184957 | 0.83 | NPC1 (0.48) | BCHEACHEHDAC3HDAC1HDAC2 | |
| SCHEMBL8850877 | 0.82 | HDAC3 (0.59) | BCHEACHEHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-7968545-B2 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INC. (US) | 2011-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | KCNQ1, KCNN2, KCNH3 | BCHE 1308/4885ACHE 280/4885HDAC3 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.